There have been studies showing the occurrence of anti-TNF-α-induced lupus-like syndrome, systemic lupus erythematosus, interstitial lung disease, new-onset or worsening of psoriasis, and cutaneous and systemic vasculitis at average intervals of 16.2-34.5 months following the onset of treatment [13]. This evidence concerns the gene TNF and interstitial lung disease.